- United States
Shareholders Will Most Likely Find Incyte Corporation's (NASDAQ:INCY) CEO Compensation Acceptable
CEO Herve Hoppenot has done a decent job of delivering relatively good performance at Incyte Corporation (NASDAQ:INCY) recently. In light of this performance, CEO compensation will probably not be the main focus for shareholders as they go into the AGM on 26 May 2021. Based on our analysis of the data below, we think CEO compensation seems reasonable for now.
Check out our latest analysis for Incyte
Comparing Incyte Corporation's CEO Compensation With the industry
At the time of writing, our data shows that Incyte Corporation has a market capitalization of US$18b, and reported total annual CEO compensation of US$16m for the year to December 2020. We note that's an increase of 8.1% above last year. We think total compensation is more important but our data shows that the CEO salary is lower, at US$1.1m.
In comparison with other companies in the industry with market capitalizations over US$8.0b , the reported median total CEO compensation was US$18m. From this we gather that Herve Hoppenot is paid around the median for CEOs in the industry. Furthermore, Herve Hoppenot directly owns US$19m worth of shares in the company, implying that they are deeply invested in the company's success.
On an industry level, roughly 19% of total compensation represents salary and 81% is other remuneration. It's interesting to note that Incyte allocates a smaller portion of compensation to salary in comparison to the broader industry. If total compensation is slanted towards non-salary benefits, it indicates that CEO pay is linked to company performance.
A Look at Incyte Corporation's Growth Numbers
Incyte Corporation saw earnings per share stay pretty flat over the last three years. It achieved revenue growth of 21% over the last year.
This revenue growth could really point to a brighter future. And the modest growth in EPS isn't bad, either. So while performance isn't amazing, we think it really does seem quite respectable. Moving away from current form for a second, it could be important to check this free visual depiction of what analysts expect for the future.
Has Incyte Corporation Been A Good Investment?
With a total shareholder return of 23% over three years, Incyte Corporation shareholders would, in general, be reasonably content. But they probably don't want to see the CEO paid more than is normal for companies around the same size.
Seeing that the company has put up a decent performance, only a few shareholders, if any at all, might have questions about the CEO pay in the upcoming AGM. In saying that, any proposed increase to CEO compensation will still be assessed on how reasonable it is based on performance and industry benchmarks.
Whatever your view on compensation, you might want to check if insiders are buying or selling Incyte shares (free trial).
Important note: Incyte is an exciting stock, but we understand investors may be looking for an unencumbered balance sheet and blockbuster returns. You might find something better in this list of interesting companies with high ROE and low debt.
If you’re looking to trade Incyte, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
Valuation is complex, but we're helping make it simple.
Find out whether Incyte is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally.
Flawless balance sheet with reasonable growth potential.